Lipid lowering activity of cerivastatin in patients with ischemic heart disease

This double-blind, placebo-controlled, parallel-group study evaluated effic acy and safety of cerivastatin 0,2 and 0,4 mg. Patients (pts) with primary hypercholesterolaemia and CAD were randomized after 8 weeks of AHA Step I d iet to treatme:it with cerivastatin (n=17) 0,2 mg for 4 weeks and 0,4 mg fo r next 4 weeks, or placebo (n=17). Cerivastatin 0,2 and 0,4 mg reduced mean TC. LDL-C, and TC by 22 and 27% (p<0,001), 28 and 34% (p<0,001) and 17 and 26% (p<0,01) respectively Mean HDL-C was elevated by 7% (p<0,01) H 6% (p<0 ,05) only in pts with low baseline HDLC level. Cerivastatin 0,4 mg also red used apo-B and apo-B/apo-Al by 33% (p<0,001) and 30% (p<0,001) respectively Cerivastatin was well tolerated and is effective and safe treatment for pt s with CAD and primary hypercholesterolaemia.